<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Heller, Simon</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Liraglutide is a Safe and Beneficial Adjunct to Insulin in Glycemic Control in Type 1 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">This article reports on the short-term findings of a randomized, double-blind, placebo-controlled crossover trial that demonstrated the prowess of the glucagon-like peptide-1 analogue liraglutide, used as an adjunct to insulin, in promoting glycemic control in type 1 diabetes [Heller SR et al. EASD 2013 (abstr 3); NCT01536665].</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>